Since early August, the world’s most valuable pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), has put on a stellar ...

But Eli Lilly's Zepbound is best in class. Zepbound caused greater average weight loss than Wegovy in a head-to-head study.

Eli Lilly (LLY) has shown considerable rally potential, with several occurrences of its stock climbing over 30% in less than ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly hiked its revenue growth guidance by 7%, while Novo Nordisk was forced to slash its targets by ~12%. See why I'm ...

Eli Lilly ( LLY 2.00%) recently announced stellar results from a phase 3 clinical trial, Triumph-4, which evaluated efficacy ...

Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection ...

Novo Nordisk receives FDA approval for its oral weight-loss pill. Analyst says NVO stock might now have an edge over Eli Lilly.

As investors look beyond mega-cap tech for the next leg of growth, pharma is quietly moving back into focus — and no two ...

Hyderabad: Global pharma heavyweights Eli Lilly and Novo Nordisk are racing to lock in market leadership in India’s blooming ...

Abivax (ABVX) stock surged on Obefazimod trial success and takeover rumors. Learn if valuation risks now outweigh reward.

Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...